The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

Publications

Maimon N, Ferguson ND, Marras TK

Angiotensin converting enzyme inhibitor toxicity causing interstitial pneumonitis and cholestatic hepatitis.

European journal of internal medicine. 2006;17(1):73

Slesnick TC, Mott AR, Fraser CD Jr, Chang AC

Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.

Pediatric cardiology. 2005;26(5):690-3

Watanabe K, Nishimura K, Shiode M, Sekiya M, Ikeda S, Inoue Y, Iwanaga C

Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia.

Internal medicine (Tokyo, Japan). 1996;35(2):142-5

Schatz PL, Mesologites D, Hyun J, Smith GJ, Lahiri B

Captopril-induced hypersensitivity lung disease. An immune-complex-mediated phenomenon.

Chest. 1989;95(3):685-7